| Conferences \ Circulating Biomarkers World Congress 2016 \ RNA-Seq, Digital PCR, and Liquid Biopsies: Capturing Value from Circulating Biomarkers \ Agenda \ John F. Beeler |
| Register | Login |
Addressing the Challenges Confronting Molecular Tumor Profiling By Demonstrating Clinical Utility of ctDNAMonday, 21 March 2016 at 17:00  Add to Calendar ▼2016-03-21 17:00:002016-03-21 18:00:00Europe/LondonAddressing the Challenges Confronting Molecular Tumor Profiling By Demonstrating Clinical Utility of ctDNASELECTBIOenquiries@selectbiosciences.comHarnessing the potential of circulating cell-free tumour DNA (ctDNA) from blood as a source of a liquid biopsy is a “game-changer,” as it ushers in a new generation of molecular applications poised to impact the major aspects of a patient’s care including treatment stratification and response monitoring. This liquid biopsy approach offers the opportunity to improve and/or resolve many of the limitations inherent in current molecular tumor profiling approaches This presentation will address the current challenges associated with molecular tumor profiling and propose how these limitations can be overcome by employing a proprietary technology based on tagged-amplicon sequencing (TAm-Seq) to analyze ctDNA and address critical clinical decision points for enhance personalized medicine applications. |
Add to Calendar ▼2016-03-21 00:00:002016-03-22 00:00:00Europe/LondonRNA-Seq, Digital PCR, and Liquid Biopsies: Capturing Value from Circulating BiomarkersSELECTBIOenquiries@selectbiosciences.com
